BioInvent International
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
Description
BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-05 15:17 |
BioInvent presents positive first clinical data on anti-FcyRIIB antibody BI-1607
|
English | 68.1 KB | ||
| 2023-12-05 15:17 |
BioInvent presenterar positiva kliniska data för anti-FcyRIIB-antikroppen BI-16…
|
Swedish | 68.9 KB | ||
| 2023-11-03 17:00 |
BioInvent presents positive data at SITC from clinical Phase 1/2a trial of BI-1…
|
English | 73.4 KB | ||
| 2023-11-03 17:00 |
BioInvent presenterar positiva data på SITC från klinisk fas 1/2a-studie med BI…
|
Swedish | 74.7 KB | ||
| 2023-10-26 08:00 | Swedish | 1.9 MB | |||
| 2023-10-26 08:00 | English | 1.9 MB | |||
| 2023-08-30 08:00 | Swedish | 1.7 MB | |||
| 2023-08-30 08:00 | English | 1.7 MB | |||
| 2023-06-21 07:30 |
BioInvent rapporterar starka interims-säkerhetsdata och tidiga signaler på effe…
|
Swedish | 68.4 KB | ||
| 2023-06-21 07:30 |
BioInvent reports strong interim safety data and early signs of efficacy in Pha…
|
English | 68.5 KB | ||
| 2023-06-07 13:05 |
BioInvent announces additional efficacy data from intravenous part of Phase 1/2…
|
English | 70.4 KB | ||
| 2023-06-07 13:05 |
BioInvent meddelar ytterligare effektdata från den intravenösa delen av fas 1/2…
|
Swedish | 70.6 KB | ||
| 2023-05-25 07:30 |
BioInvent and Transgene report positive Phase 1a data on oncolytic virus BT-001…
|
English | 76.5 KB | ||
| 2023-05-25 07:30 |
BioInvent och Transgene rapporterar positiva fas 1a-data för det onkolytiska vi…
|
Swedish | 76.4 KB | ||
| 2023-04-27 17:25 |
Resolutions at BioInvent’s Annual General Meeting 2023
|
English | 61.8 KB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
